SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Eagle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until February 10, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Eagle securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On November 9, 2023, before the market opened, Ea
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida [Acquire Media Monitor
- Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaGlobeNewswire
- Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K [Yahoo! Finance]Yahoo! Finance
- Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KGlobeNewswire
- Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE)Accesswire
EGRX
Earnings
- 8/8/23 - Beat
EGRX
Sec Filings
- 4/12/24 - Form 8-K
- 3/18/24 - Form SC
- 3/18/24 - Form NT
- EGRX's page on the SEC website